G21.2
Secondary parkinsonism due to other external agents
Clinical Classification Guidelines
Code First
- (T51-T65) to identify external agent
Medical Intelligence & Overview
Secondary parkinsonism, classified under ICD-10 code G21.2, is a condition where Parkinson-like symptoms develop due to exposure to external substances or agents. Unlike primary Parkinson's disease, which is a neurodegenerative disorder with no clear external cause, secondary parkinsonism results from identifiable external factors or toxins affecting the nervous system. This form of parkinsonism can manifest after exposure to certain medications, toxins, or other external agents that interfere with normal brain functioning, particularly in areas responsible for movement control. Recognizing and understanding this condition is essential for appropriate management and to prevent further neurological damage.
Causes & Symptoms
Clinical Causes: Use of dopamine-blocking medications (e.g., phenothiazines, butyrophenones, metoclopramide) Exposure to environmental toxins such as manganese, carbon monoxide, or certain pesticides Chemical poisoning from substances like neurotoxins or heavy metals Trauma or injury to the brain that affects movement-related regions Prolonged use of certain drugs or substances that interfere with dopamine pathways
Key Symptoms: Bradykinesia (slowness of movement) Muscular rigidity or stiffness Resting tremor, often noticeable in the hands or jaw Postural instability and impaired balance Reduced facial expressions (hypomimia) Shuffling gait and difficulty initiating movement Speech changes, such as softening or slurring Difficulty with coordination and fine motor skills Possible autonomic dysfunctions like blood pressure fluctuations
Diagnostic & Treatment
Diagnosis Path: Diagnosing secondary parkinsonism involves a comprehensive clinical evaluation, including a detailed medical history to identify potential external agents or exposures. Neurological examinations are performed to assess motor and non-motor symptoms. Additional investigations such as neuroimaging (MRI or CT scans) may be used to rule out other causes like stroke or tumors. Blood tests may also be conducted to identify toxin levels or identify underlying metabolic issues. In some cases, a trial of discontinuing suspected offending agents can help determine if symptoms improve, supporting a diagnosis of secondary parkinsonism.
Treatment Protocols: Treatment strategies focus primarily on addressing the underlying cause when possible, such as removing exposure to toxins or discontinuing offending medications. Symptomatic management may include the use of antiparkinsonian medications like levodopa, although responses can vary. Supportive therapies, including physical, occupational, and speech therapy, are important for improving mobility, daily functioning, and communication. Additionally, regular monitoring and adjustments to treatment plans are crucial to manage symptoms effectively. Safety precautions to prevent falls and injuries are also recommended for individuals experiencing movement difficulties.
Clinical Advice & FAQs
Billing Guidance
Is G21.2 a billable ICD-10 code?
Yes, G21.2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G21.2?
Clinical documentation must specify the nature of Secondary parkinsonism due to other external agents and any associated comorbidities for accurate reporting.
Cite this Clinical Reference